Shinsuke Iida

Mogamulizumab versus vorinostat in previously treated cutaneous T-cell lymphoma (MAVORIC): an international, open-label, randomised, controlled phase 3 trial

Youn H. Kim, M. Bagot, Lauren Pinter‐Brown et al. · The Lancet Oncology · 2018 · 645 citations · Full text

Medicine, Oncology, Pharmacotherapy +13

Isatuximab plus pomalidomide and low-dose dexamethasone versus pomalidomide and low-dose dexamethasone in patients with relapsed and refractory multiple myeloma (ICARIA-MM): a randomised, multicentre, open-label, phase 3 study

Michel Attal, Paul G. Richardson, S. Vincent Rajkumar et al. · The Lancet · 2019 · 636 citations

Medicine, Hematology, Pharmacotherapy +15

Elranatamab in relapsed or refractory multiple myeloma: phase 2 MagnetisMM-3 trial results

Alexander M. Lesokhin, Michael H. Tomasson, Bertrand Arnulf et al. · Nature Medicine · 2023 · 564 citations · Full text

Medicine, Oncology, Pharmacotherapy +17

Familial essential thrombocythemia associated with a dominant-positive activating mutation of the c-MPL gene, which encodes for the receptor for thrombopoietin

Jianmin Ding, Hirokazu Komatsu, Atsushi Wakita et al. · Blood · 2004 · 365 citations · Full text

Medicine, Genetics, Hematology +14

Clinical significance of CCR4 expression in adult T-cell leukemia/lymphoma: its close association with skin involvement and unfavorable outcome.

Takashi Ishida, Atae Utsunomiya, Shinsuke Iida et al. · PubMed · 2003 · 354 citations

Medicine, Hematology, Oncology +14